AstraZeneca monoclonal antibody works against omicron, studies show
New studies are offering additional reassurance that AstraZeneca's monoclonal antibody drug works against omicron.
The company's EVUSHELD retains neutralization activity against omicron, according to "live" virus neutralization data from both University College Oxford and Washington University School of Medicine.
AstraZeneca announced last week that its antibody drug would likely retain protection against omicron. These studies add to that growing evidence.
AstraZeneca's monoclonal antibody was authorized on Dec. 8, but for a narrow group of people. It is authorized as a way to prevent COVID-19 among people who are immune compromised, or people who are allergic to vaccine components. It is not authorized as a way to treat COVID-19 among people who have already tested positive.
There are three monoclonal antibody treatments currently authorized to treat people who already have COVID-19. Two of those treatments -- those made by Eli Lilly and Regeneron -- appear to have very little activity against omicron. A third treatment, made by Vir and GlaxoSmithKline, appears to work against omicron but is currently in short supply. The companies are working to scale up production.
-ABC News' Sony Salzman